公开(公告)号：US20180327402A1

公开(公告)日：2018-11-15

申请号：US15975462

申请日：2018-05-09

Applicant: Genentech, Inc.

Inventor： Simon Charles Goodacre ,  Nicholas Charles Ray ,  Mark Edward Zak ,  Yun-Xing Cheng ,  Wei Li

IPC: C07D471/04 ,  C07D471/10

CPC classification number: C07D471/04 ,  C07D471/10

Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.

公开(公告)号：US20180297997A1

公开(公告)日：2018-10-18

申请号：US16009596

申请日：2018-06-15

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Rongbao Hua ,  Terry Kellar ,  Wei Li ,  Paul Gibbons ,  Mark Edward Zak

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06

CPC classification number: C07D471/04 ,  A61P11/06 ,  C07D519/00

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20170226132A1

公开(公告)日：2017-08-10

申请号：US15499662

申请日：2017-04-27

Applicant: Genentech, Inc.

Inventor： Nicholas C. Ray ,  Yun-Xing Cheng ,  Christine Edwards ,  Simon C. Goodacre ,  Wei Li ,  Snahel Patel ,  Matthew W. Cartwright ,  Mohammed Sajad ,  Po-wai Yuen ,  Mark E. Zak

IPC: C07D519/00 ,  C07D471/04

CPC classification number: C07D519/00 ,  C07D471/04

Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US09266961B2

公开(公告)日：2016-02-23

申请号：US13918755

申请日：2013-06-14

Applicant: Genentech, Inc.

Inventor： Yan Wu ,  Cecilia Pui Chi Chiu ,  Daniel K. Kirchhofer ,  Andrew Peterson ,  Ganesh A. Kolumam ,  Monica Kong Beltran ,  Paul Moran ,  Wei Li ,  Xanthe M. Lam ,  Lin Luis ,  Ada Hui

IPC: C07K16/40 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K39/39591 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.

Abstract translation: 本发明提供抗PCSK9抗体，制剂，给药方案及其使用方法。

公开(公告)号：US20140212431A1

公开(公告)日：2014-07-31

申请号：US14133986

申请日：2013-12-19

Applicant: Genentech, Inc.

Inventor： Daniel K. Kirchhofer ,  Yingnan Zhang ,  Andrew Scott Peterson ,  Wei Li ,  Monica Kong-Beltran ,  Lijuan Zhou

IPC: C07K16/40 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K31/40 ,  A61K38/1808 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K14/485 ,  C07K2317/70 ,  C07K2319/30 ,  C12N9/6454 ,  A61K31/22 ,  A61K31/365 ,  A61K31/366 ,  A61K31/404 ,  A61K31/505

Abstract: The invention provides PCSK9-binding polypeptides and methods of using the same.

Abstract translation: 本发明提供PCSK9结合多肽及其使用方法。

公开(公告)号：US20220204517A1

公开(公告)日：2022-06-30

申请号：US17654131

申请日：2022-03-09

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Paul Gibbons ,  Terry Kellar ,  Wei Li ,  Rohan Mendonca ,  Po-wai Yuen ,  Mark Edward Zak ,  Lei Zhang

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20220106322A1

公开(公告)日：2022-04-07

申请号：US17644742

申请日：2021-12-16

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Wei Li ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US11155557B2

公开(公告)日：2021-10-26

申请号：US16452058

申请日：2019-06-25

Applicant: Genentech, Inc.

Inventor： F. Anthony Romero ,  Mark Zak ,  Guiling Zhao ,  Paul Gibbons ,  Wei Li ,  Yun-Xing Cheng ,  Po-Wai Yuen ,  Limin Cheng

IPC: C07D487/04 ,  C07D498/10

Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US10787484B2

公开(公告)日：2020-09-29

申请号：US16229226

申请日：2018-12-21

Applicant: Genentech, Inc.

Inventor： Maureen Beresini ,  Daniel Burdick ,  Charles Eigenbrot, Jr. ,  Daniel Kirchhofer ,  Robert Lazarus ,  Wei Li ,  John Quinn ,  Nicholas Skelton ,  Mark Ultsch ,  Yingnan Zhang

IPC: C07K7/06 ,  C07K7/02 ,  C12N9/64 ,  C12Q1/37 ,  G01N33/573 ,  G01N33/92 ,  C40B40/10 ,  C07K14/00 ,  A61K47/62 ,  A61P3/06 ,  A61K38/00

Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

公开(公告)号：US20190337946A1

公开(公告)日：2019-11-07

申请号：US16515253

申请日：2019-07-18

Applicant: Genentech, Inc.

Inventor： Simon Charles Goodacre ,  Nicholas Charles Ray ,  Mark Edward Zak ,  Yun-Xing Cheng ,  Wei Li

IPC: C07D471/04 ,  C07D471/10

Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.